Loading...
Natco Pharma Shares Soar Nearly 11% Today: What Drove the Surge?
LIVE TV
LOCAL
ENGLISH
For You
Entertainment
National
Sports
Markets
Business & Economy
Lifestyle
World
Astrology & Religion
Technology
Education & Jobs
Auto
Politics
Viral
Opinions
Loading more articles...
Home
Local
Live TV
Natco Pharma Shares Soar 11% on CDSCO Nod for Semaglutide Injection
C
CNBC TV18
•
16-02-2026, 10:41
Natco Pharma Shares Soar 11% on CDSCO Nod for Semaglutide Injection
•
Natco Pharma shares surged 11% after receiving CDSCO approval for its semaglutide injection.
•
The company plans to launch the generic semaglutide injection in Indian markets by March.
•
Semaglutide is a weight loss drug for adults with inadequately controlled type 2 diabetes mellitus.
•
USFDA issued an Establishment Inspection Report (EIR) with seven observations for Natco Pharma's Chennai API unit, classifying it as VAI.
•
The company reported a 14.3% YoY increase in consolidated net profit and a 36.3% rise in revenue for the December quarter.
Read Full Article on Cnbc in English
✦
More like this
✦
More like this
Natco Pharma Shares Dip After USFDA Issues 7 Observations for Chennai Unit
C
CNBC TV18
Indoco Remedies Shares Soar 7% on USFDA Approval for Brivaracetam Oral Solution
C
CNBC TV18
Indian REITs Distribute Rs 2,450 Crore to Unitholders in Q3FY26
N
News18
Q3 Results: 7 Companies See Earnings Boost, One Doubles Profit
C
CNBC Awaaz
15 Stocks to Watch on Feb 13: Quarterly Results, Dividends, Management Changes
M
Moneycontrol
Ramco Cements Stock Crashes 5% After Disappointing Q3 Results, Market Reacts to Weak Performance
C
CNBC Awaaz
